Written by the Nuvirox Research Team
Key points
- Hypoxia (low oxygen) rapidly depletes cellular NAD+, and in mice, NAD+ precursors protect brain tissue from some effects of simulated high-altitude exposure.
- There is no published human trial testing NAD+ precursors for altitude sickness prevention or treatment.
- A separate animal study actually found nicotinamide riboside reduced exercise performance, an important honest counterweight to any 'boosts altitude performance' framing.
Short answer: the mechanism is real, but the human proof isn't there yet, and even the exercise-performance data is mixed. Here's what altitude and hypoxia research on NAD+ actually shows, without the marketing gloss.
Why would altitude affect your NAD+ levels?
Climbing to high altitude drops the partial pressure of oxygen available to your cells. Since NAD+ is central to how mitochondria generate energy using oxygen, this hypoxic stress increases oxidative and nitrosative damage and drives up activity of NAD+-consuming repair enzymes like PARP, which can further deplete the cellular NAD+ pool. That combination — more damage, less repair currency — is thought to underlie some of the cognitive fog, fatigue, and impaired recovery people experience at altitude.
What does the evidence actually show?
A 2025 study simulated an altitude of roughly 6,000 meters in mice over two weeks and found that hypoxia impaired hippocampal learning and memory function, along with measurable loss of dendritic spine density — a marker of impaired brain connectivity. Nicotinamide riboside administration significantly increased hippocampal NAD+ and NMN levels and reduced this neurotoxic damage, apparently by dampening an overactive microglial (brain immune cell) response to the hypoxic stress.
Study snapshot: NR and hypoxia-induced brain injury (mouse model)
| Design | Controlled animal study, simulated 6,000m altitude |
| Duration | 2-week hypoxia exposure |
| Finding | NR increased hippocampal NAD+, reduced dendritic spine loss and memory impairment |
| Species | Mouse (hippocampal tissue) |
The honest counterweight
Two things temper this considerably. First, there is no published human trial of NAD+ precursors for altitude sickness, acclimatization, or high-altitude cognitive performance — the entire evidence base above is preclinical. Second, and more surprisingly, a controlled study in rats found that 21 days of nicotinamide riboside supplementation actually trended toward worse, not better, exercise performance on an incremental swimming test (a non-significant 35% reduction at the highest workload). The authors concluded their results "do not confirm the previously reported ergogenic effect" of NR. That's a useful reminder that NAD+ biology is complex enough that raising it doesn't uniformly translate into better physical performance, at altitude or otherwise.
When to see a doctor
Altitude sickness (acute mountain sickness) can progress to high-altitude pulmonary or cerebral edema, which are medical emergencies. If you or someone you're with develops severe headache, confusion, breathlessness at rest, or a persistent cough at altitude, descend and seek medical care immediately — this is not a situation for a wait-and-see supplement approach.
What's actually proven to help with altitude
Gradual ascent (the single most effective strategy), acetazolamide as a preventive medication in appropriate candidates, adequate hydration, and avoiding alcohol during acclimatization all have solid evidence behind them. Descent remains the definitive treatment for worsening altitude illness.
How does this relate to NAD+ and exercise research generally?
Altitude performance sits at the intersection of hypoxia tolerance and general exercise physiology, and it's worth reading the broader picture in our coverage of NAD+ and exercise performance, where the human trial evidence (including a real randomized trial in peripheral artery disease patients showing improved walking distance) is more substantial than what exists for altitude specifically. If cellular energy support during physically demanding situations is your actual goal, that's a better-evidenced angle than altitude sickness prevention specifically, and our page on mitochondria supplements covers which ingredients have real trial support for that broader goal.
It's also worth understanding why altitude research specifically lags behind other NAD+ applications: high-altitude human trials are logistically difficult and expensive to run (requiring either travel to genuine altitude or specialized hypobaric chambers), which is part of why this research area remains almost entirely preclinical despite the mechanistically sound hypoxia-NAD+ connection. For everyday energy support rather than altitude-specific claims, see our overview of NAD+ and energy.
Worth adding some numeric context: the rat exercise study used a substantial 300 mg/kg body weight daily dose for 21 days, roughly proportional to a very high human dose if scaled directly (scaling animal-to-human doses isn't linear, so this isn't a direct human dosing recommendation, just useful context for interpreting the study). The nonsignificant trend toward worse performance at the highest workload is the kind of finding that, if replicated, would meaningfully complicate any simple "more NAD+ equals better performance" narrative.
If you're planning a high-altitude trip and are drawn to the idea of a supplement-based edge, it's worth weighing that against what's actually been tested in humans: acetazolamide has decades of altitude-specific human trial data, while NAD+ precursors have none in this context. That's not a reason to avoid a general NAD+ precursor for unrelated wellness goals, but it is a reason not to count on one for altitude-specific protection.
It's also worth distinguishing acute mountain sickness (the common headache-and-fatigue syndrome most travelers experience) from the rarer, more dangerous high-altitude pulmonary and cerebral edema, since the hypoxia research on NAD+ described above is studying general cellular stress responses to low oxygen, not specifically targeting either the common or the severe presentations differently. Researchers exploring this pathway are, at this stage, mostly interested in the underlying biology rather than any specific clinical altitude-illness endpoint.
For most travelers, the practical takeaway is simple: plan a gradual ascent schedule first, and treat any supplement as a secondary, unproven consideration rather than a core part of your altitude preparation plan. Guidebooks and travel clinics specializing in high-altitude trekking can help you build an ascent schedule appropriate to your specific route and starting elevation.
Consider a consultation with a travel medicine clinic before any high-altitude trip above roughly 2,500 meters, especially if you have a personal history of altitude illness or a cardiopulmonary condition that could meaningfully raise your individual risk during ascent.
That single planning step matters more than any supplement choice you'll make for the trip.
Frequently asked questions
Will an NAD+ supplement help me acclimatize faster?
There's no human evidence for this. The supporting research is limited to animal hypoxia models.
Does raising NAD+ improve athletic performance at altitude or otherwise?
The evidence is genuinely mixed; at least one animal study found no ergogenic benefit and a nonsignificant trend toward worse performance.
What's the single best-proven way to prevent altitude sickness?
Ascending gradually and allowing time to acclimatize, sometimes combined with preventive acetazolamide under medical guidance, has the strongest evidence.
From Nuvirox
Why we formulated NAD+ Restore
If you're exploring ways to support cellular energy and healthy aging more broadly, this is where NAD+ Restore fits in.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: hypoxia genuinely stresses your cellular NAD+ system, and that's a mechanistically sound story worth knowing — but it hasn't been tested in humans at altitude, and NAD+ precursor research on physical performance overall is more mixed than confident marketing claims suggest.
References
- Nicotinamide Riboside Alleviates the Neurotoxic Injury of Dendritic Spine Plasticity Mediated by Hypoxic Microglial Activation. Biomolecules. 2025. doi:10.3390/biom15101391.
- The NAD+ precursor nicotinamide riboside decreases exercise performance in rats. J Int Soc Sports Nutr. PMCID: PMC4971637.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.